article thumbnail

Cigna's Express Scripts to cross out AbbVie's Humira from some formularies in 2025, opting to go with biosims instead

Fierce Pharma

When CVS Caremark removed AbbVie’s Humira from its national commercial formularies back in April, biosimilar prescriptions picked up at a whirlwind pace. Following CVS Caremark's lead, Cigna's pharmacy benefit manager unit will nix Humira from formularies in favor of Humira biosimilars from Boehringer Ingelheim, Teva and Sandoz.

article thumbnail

FDA accepts Eisai's subcutaneous Leqembi filing, sets January 25 decision date

Fierce Pharma

The FDA assigned the subcutaneous Leqembi application a Prescription Drug User Fee Act decision date of January 25, 2025. About a month after Eisai initiated a rolling FDA application for its subcutaneous form of Leqembi, the U.S. agency has accepted the filing. |

FDA 241
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Medicare Advantage Star Ratings Drop Again

MedCity News

For 2025, the average star rating for Medicare Advantage Prescription Drug contracts was 3.92, compared to 4.07 for 2024, 4.14 for 2023 and 4.37 The post Medicare Advantage Star Ratings Drop Again appeared first on MedCity News.

article thumbnail

Are new weight loss drugs an answer or problem?

World of DTC Marketing

Novo Nordisk more than doubled its sales targets for obesity drugs to $3.7bn by 2025. Payers also face hurdles, so patients must obtain permission before filling a prescription. One Maryland pharmacist told me she had seen many prescriptions for Wegovy, none of which had ever come back after being sent for authorization. .

article thumbnail

Medicare Part D: Navigating Plans and Potential Gaps in 2025

Pharmaceutical Commerce

With a 26% decline in prescription drug plans from 2024 to 2025, navigating potential gaps and accessing care remains vital for low income patients.

article thumbnail

GSK eyes up combo approval for previously withdrawn myeloma drug

Pharmaceutical Technology

The US Food and Drug Administration (FDA) is expected to make a Prescription Drug User Fee Act (PDUFA) decision by mid-2025.

article thumbnail

Highlights from The Data Ecosystem in 2025

Prognos Health

Prognos CEO Sundeep Bhan was a featured panelist in a session titled The Data Ecosystem in 2025 , which also included leaders from CVS Health, Komodo Health, and Blue Health Intelligence Ⓡ (BHI Ⓡ ). ” The post Highlights from The Data Ecosystem in 2025 appeared first on Prognos Health.